Form 4: Arcellx Director Olivia C Ware Reports Stock Option Grant

Director Olivia C Ware reports acquisition of 8,011 stock options in Arcellx, Inc.

Summary

• On May 28, 2024, Olivia C Ware, a director of Arcellx, Inc. (ACLX), was granted stock options to purchase 8,011 shares of common stock.
• The exercise price of these options is $51.30 per share.
• The options vest on the earlier of May 28, 2025, or the next annual meeting of stockholders, contingent upon continued service as a Service Provider as defined in the 2022 Equity Incentive Plan.
• The options expire on May 28, 2034.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants, a common practice for incentivizing company leadership.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain talent, aligning their interests with the long-term success of the company. This is a standard incentive mechanism.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in biotech companies like Arcellx.
• Comparable companies such as CRISPR Therapeutics, Beam Therapeutics, and Editas Medicine also utilize stock options as part of their compensation strategy to incentivize performance and align executive interests with shareholder value.
• The vesting schedule and exercise price are within the typical range observed in similar grants within the industry.

Stakeholder Impact

• The stock option grant could have a minor dilutive effect on existing shareholders if the options are exercised in the future.

Key Dates